Invesco Nasdaq Biotechnology ETF
IBBQ - ETF AI Analysis
Top Page
Invesco Nasdaq Biotechnology ETF (IBBQ)
IBBQ, the Invesco Nasdaq Biotechnology ETF, has a solid overall rating driven mainly by strong, established biotech leaders like Gilead, Amgen, Vertex, Regeneron, and Royalty Pharma, which show robust financial performance, healthy pipelines, and generally favorable long-term outlooks. However, weaker names such as Moderna and Revolution Medicines, which face revenue declines, ongoing losses, and bearish technical trends, weigh on the fund’s quality. The main risk factor is its concentrated exposure to the biotechnology sector, meaning the ETF’s performance is heavily tied to the fortunes and volatility of biotech companies.
IBBQ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 131.39M
- Region
- North America
- Expense Ratio
- 0.19%
- Beta
- 0.76
- Issuer
- Invesco
- Inception Date
- Jun 11, 2021
- Dividend Yield
- 1.07%
- Asset Class
- Equity
- Index Tracked
- NASDAQ / Biotechnology
IBBQ Summary
IBBQ is the Invesco Nasdaq Biotechnology ETF, which follows the Nasdaq Biotechnology Index. It focuses on U.S. health care companies in biotech and pharmaceuticals, giving you a way to invest in firms working on new drugs, vaccines, and medical treatments. Well-known holdings include Gilead Sciences and Amgen. Someone might invest in IBBQ to tap into the long-term growth potential of innovative biotech companies while getting diversification across many stocks instead of picking just one. A key risk is that biotech shares can be very volatile, so the ETF’s value can rise and fall sharply with news, drug approvals, or market swings.
How much will it cost me?
IBBQ has an expense ratio of 0.19%, which means you’ll pay about $1.90 per year for every $1,000 invested. This cost is slightly higher than the cheapest broad-market index ETFs but still reasonable for a specialized, passively managed biotech sector fund.
What would affect this ETF?
IBBQ could benefit if demand for new medicines and biotech innovations grows, helping major U.S. holdings like Gilead, Amgen, Vertex, and Moderna, especially when health care spending is strong and regulation is supportive. On the downside, stricter drug pricing rules, setbacks in clinical trials, or a weaker U.S. economy could hurt these companies, and changes in interest rates or investor sentiment toward riskier sectors may also weigh on this biotech-focused ETF.
IBBQ Top 10 Holdings
IBBQ is essentially a bet on big U.S. biotech, with heavyweights like Amgen, Gilead, Vertex, and Regeneron steering the ship. These names have been steadily rising, giving the fund a solid core of profitable, established drug makers. Moderna adds more drama, with sharp recent gains driven by momentum rather than stable fundamentals, while Illumina’s rebound in genomics has helped brighten the picture. On the flip side, Alnylam and Revolution Medicines are more mixed and occasionally drag on returns, reminding investors this is a high‑innovation, high‑volatility corner of health care.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GILD | Gilead Sciences | 8.97% | $11.47M | $211.94B | 44.62% | 78Outperform |
 AMGN | Amgen | 8.42% | $10.78M | $251.65B | 43.74% | 77Outperform |
 VRTX | Vertex Pharmaceuticals | 7.90% | $10.11M | $138.91B | 30.08% | 78Outperform |
 MRNA | Moderna | 6.53% | $8.35M | $101.49B | 913.05% | 59Neutral |
 REGN | Regeneron | 5.88% | $7.52M | $94.75B | 39.91% | 78Outperform |
 RVMD | Revolution Medicines | 2.65% | $3.39M | $41.76B | 207.76% | 52Neutral |
 BIIB | Biogen | 2.36% | $3.02M | $37.44B | 62.07% | 74Outperform |
 ILMN | Illumina | 2.07% | $2.65M | $32.49B | 76.56% | 71Outperform |
 RPRX | Royalty Pharma | 1.93% | $2.47M | $39.84B | 80.20% | 79Outperform |
 ROIV | Roivant Sciences | 1.81% | $2.31M | $29.84B | 94.57% | 58Neutral |
IBBQ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBBQ, the sentiment is Positive. The current price of 36.46 is above the 20-day moving average (MA) of 35.35, above the 50-day MA of 34.97, and above the 200-day MA of 31.58, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 56.97 is Neutral, neither overbought nor oversold. The STOCH value of 72.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBBQ.
IBBQ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IBBQ | $36.46 | $38.00(4.22% Upside) | $131.39M | 0.19% | 65Neutral |
 PJP | $130.54 | $160.98(23.32% Upside) | $600.27M | 0.58% | 70Neutral |
 XPH | $67.93 | $104.39(53.68% Upside) | $477.16M | 0.35% | 58Neutral |
 PBE | $99.62 | $128.62(29.11% Upside) | $443.95M | 0.59% | 70Outperform |
 PINK | $40.63 | $48.36(19.03% Upside) | $348.97M | 0.51% | 67Neutral |
 LFSC | $46.69 | $68.16(45.96% Upside) | $125.23M | 0.54% | 50Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IBBQ | Invesco Nasdaq Biotechnology ETF | 36.46 | 9.22 | 33.85% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 130.54 | 29.30 | 28.94% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 67.93 | 17.26 | 34.07% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 99.62 | 22.43 | 29.05% | |
| PINK | Simplify Health Care ETF | 40.63 | 6.12 | 17.74% | |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 46.69 | 11.85 | 34.02% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.